Washington Area Comprehensive Sickle Cell Center

华盛顿地区综合镰状细胞中心

• 批准号: 7821241
• 负责人: SOHAIL RANA
• 金额: $ 40.98万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-18 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7821241
• 关键词: Washington; Area; Comprehensive; Sickle; Cell

DESCRIPTION (provided by applicant): The proposed Washington Area Comprehensive Sickle Cell Center includes Howard University, a historically-black teaching institution in the nation's capital, Children's National Medical Center, the premier provider of healthcare to children with sickle cell disease (SCD) in the area, and the Vascular Medicine Branch of NHLBI, an internationally recognized unit that leads in the investigation of the vascular complications of SCD. The proposed Center also includes collaboration with Ahmadu Bello University in Zaria, Nigeria, an institution that treats many SCD patients who have not yet been exposed to blood transfusions or hydroxyurea. The primary focus of the proposed center is to improve understanding, prevention and treatment of the vascular complications of SCD. The components of the project are: 1. An inter-Center Phase II Study of therapy with a nitric oxide-donating combination compared to an angiotensin converting enzyme inhibitor or placebo in preventing renal dysfunction, pulmonary hypertension, stroke and other complications in SCD patients with systemic systolic blood pressure of 120-139 mm Hg. 2. An intra-Center clinical study to determine the prevalence of pulmonary hypertension in Nigerian SCD patients using echocardiographic measurements of the tricuspid regurgitant jet velocity, the contribution of HIV/AIDS and malaria, and the role of genetic polymorphisms in candidate genes that regulate endothelial function and adhesion. 3. A patient services research project to identify the prevalence of developmental problems among infants and toddlers with SCD compared to age and demographically matched controls. 4. A translational research project that seeks to raise levels of HDL and therefore apoA-1 to improve endothelium-dependent vasorelaxation by administration of the NAD precursor, niacin. 5. An Administrative Core. 6. A Clinical Core that includes the adult and pediatric sickle cell clinics at Howard University, the pediatric sickle cell clinic at Children's National Medical Center, the adult sickle cell clinic at NHLBI, and their associated personnel. 7. A Patient Services Core focusing on education, community outreach, genetic counseling and diagnostic testing. 8. A Sickle Cell Scholar Component.

DESCRIPTION (provided by applicant): The proposed Washington Area Comprehensive Sickle Cell Center includes Howard University, a historically-black teaching institution in the nation's capital, Children's National Medical Center, the premier provider of healthcare to children with sickle cell disease (SCD) in the area, and the Vascular Medicine Branch of NHLBI, an internationally recognized unit that leads in the investigation of the vascular complications of SCD.拟议中心还包括与尼日利亚扎里亚的艾哈迈杜·贝洛大学（Ahmadu Bello University）合作，该机构对待许多尚未接触过输血或羟基脲的SCD患者。拟议中心的主要重点是改善对SCD血管并发症的理解，预防和治疗。该项目的组成部分是： 1。与转化酶抑制剂的血管紧张素或安慰剂相比，一项与一氧化氮组合组合的治疗中心II期研究，可预防肾功能障碍，肺动脉高压，中风和其他并发症，患有120-139 mm Hg的全身性系统性血压的SCD患者。 2。一项中心内临床研究，旨在使用超声心动图测量尼日利亚SCD患者的肺动脉高压率的流行，对三尖端反流的喷气速度，HIV/艾滋病和疟疾的贡献，以及遗传多态性在候选Genes中的作用和遗传多态性的作用。 3。与年龄和人口统计学匹配的对照相比，患者服务的患者服务研究项目旨在确定患有SCD的婴儿和幼儿的发育问题流行。 4.一个转化研究项目，旨在通过施用NAD前体烟酸来提高HDL的水平，因此旨在提高HDL水平，从而提高内皮依赖性血管结束。 5。行政核心。 6。一种临床核心，包括霍华德大学的成人和小儿镰状细胞诊所，儿童国家医疗中心的儿科镰刀诊所，NHLBI的成人镰状细胞诊所及其相关人员。 7。专注于教育，社区外展，遗传咨询和诊断测试的患者服务核心。 8。镰状细胞学者成分。